The Goldman Sachs Group Cuts Insulet (NASDAQ:PODD) Price Target to $375.00

Insulet (NASDAQ:PODD) had its price target cut by The Goldman Sachs Group from $399.00 to $375.00 in a research report sent to investors on Wednesday,MarketScreener reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other equities research analysts also recently commented on the company. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Wells Fargo & Company boosted their target price on Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Royal Bank Of Canada raised their price target on Insulet from $330.00 to $350.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Piper Sandler boosted their price objective on Insulet from $320.00 to $360.00 and gave the company an “overweight” rating in a research report on Tuesday, September 16th. Finally, Canaccord Genuity Group boosted their price objective on Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a research report on Monday. Sixteen equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average target price of $345.47.

Insulet Trading Down 1.0%

NASDAQ PODD opened at $309.11 on Wednesday. The stock has a 50-day simple moving average of $321.34 and a 200 day simple moving average of $298.54. The company has a market capitalization of $21.76 billion, a PE ratio of 93.95, a P/E/G ratio of 2.59 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet has a 12 month low of $225.37 and a 12 month high of $353.50.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. The business had revenue of $649.10 million during the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm’s revenue was up 32.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.55 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Research analysts forecast that Insulet will post 3.92 EPS for the current year.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total value of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its position in Insulet by 426.3% during the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new position in Insulet during the first quarter valued at approximately $26,000. SouthState Corp boosted its position in Insulet by 253.3% during the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. acquired a new position in Insulet during the second quarter valued at approximately $32,000. Finally, Golden State Wealth Management LLC raised its stake in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock valued at $32,000 after buying an additional 69 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.